PMID- 18209727
OWN - NLM
STAT- MEDLINE
DCOM- 20080520
LR  - 20101118
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 41
IP  - 5
DP  - 2008 Mar
TI  - Hematopoietic transplantation from adult unrelated donors as treatment for acute 
      myeloid leukemia.
PG  - 425-37
LID - 10.1038/sj.bmt.1705973 [doi]
AB  - Transplantation from unrelated donors (URD) is increasingly being used as 
      treatment for hematological malignancies, including acute myeloid leukemia (AML). 
      This increase is the consequence of the availability of more than 11 million URD 
      volunteers and the more efficient donor search process in the recent years. 
      Median time to identify a suitable URD is now 2 months. More than 50% of 
      Caucasian patients have an human leukocyte antigen (HLA)-allele donor match and a 
      one-antigen or allele HLA-mismatched donor may also be acceptable. Complications 
      of URD transplants are particularly frequent and severe, with long-term OS in the 
      registries being 10-20% inferior to HLA-identical sibling transplantation. High 
      resolution DNA techniques for donor and recipient HLA matching have contributed 
      to the survival in experienced centres after unrelated donor SCT approaching that 
      achieved with sibling donors. The introduction of reduced intensity conditioning 
      (RIC) has extended URD transplants to elderly and/or debilitated patients with 
      AML. With this approach, TRM decreases, although graft-versus-host 
      disease-related morbidity and mortality remain a problem. Despite this 
      complication, results after URD transplantation in this age group seem better 
      than those achieved with chemotherapy and/or autologous transplantation. To 
      confirm this possibility, prospective multicenter comparisons of URD transplants 
      after RIC with other treatment options for elderly AML patients have recently 
      been started.
FAU - Sierra, J
AU  - Sierra J
AD  - Clinical Hematology Division and Hematopoietic Transplant Program, Hospital de la 
      Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. 
      jsierra@santpau.es
FAU - Martino, R
AU  - Martino R
FAU - Sanchez, B
AU  - Sanchez B
FAU - Pinana, J L
AU  - Pinana JL
FAU - Valcarcel, D
AU  - Valcarcel D
FAU - Brunet, S
AU  - Brunet S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080121
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
SB  - IM
MH  - Adult
MH  - Aged
MH  - Graft vs Host Disease
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - Middle Aged
MH  - Tissue Donors
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous/adverse effects/methods
RF  - 93
EDAT- 2008/01/23 09:00
MHDA- 2008/05/21 09:00
CRDT- 2008/01/23 09:00
PHST- 2008/01/23 09:00 [pubmed]
PHST- 2008/05/21 09:00 [medline]
PHST- 2008/01/23 09:00 [entrez]
AID - 1705973 [pii]
AID - 10.1038/sj.bmt.1705973 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2008 Mar;41(5):425-37. doi: 10.1038/sj.bmt.1705973. Epub 
      2008 Jan 21.